Metachronous Bilateral Renal Cell Carcinoma: Risk Assessment, Prognosis and Relevance of the Primary-Free Interval
2007; Lippincott Williams & Wilkins; Volume: 177; Issue: 6 Linguagem: Inglês
10.1016/j.juro.2007.01.122
ISSN1527-3792
AutoresTobias Klatte, Jean‐Jacques Patard, Heiko Wunderlich, Rakhee H. Goel, John S. Lam, Kerstin Junker, Jörg Schubert, Malte Böhm, E. P. Allhoff, Fairooz F. Kabbinavar, Maxime Crépel, Luca Cindolo, Alexandre de la Taille, Jacques Tostain, Arnaud Méjean, M. Soulié, Laurent Bellec, Jean‐Christophe Bernhard, Jean-Marie Ferrière, Christian Pfister, Baptiste Albouy, Marc Colombel, Amnon Zisman, Arie S. Belldegrun, Allan J. Pantuck,
Tópico(s)Multiple and Secondary Primary Cancers
ResumoNo AccessJournal of UrologyAdult urology1 Jun 2007Metachronous Bilateral Renal Cell Carcinoma: Risk Assessment, Prognosis and Relevance of the Primary-Free Interval Tobias Klatte, Jean-Jacques Patard, Heiko Wunderlich, Rakhee H. Goel, John S. Lam, Kerstin Junker, Jörg Schubert, Malte Böhm, Ernst P. Allhoff, Fairooz F. Kabbinavar, Maxime Crepel, Luca Cindolo, Alexandre De La Taille, Jacques Tostain, Arnaud Mejean, Michel Soulie, Laurent Bellec, Jean Christophe Bernhard, Jean-Marie Ferriere, Christian Pfister, Baptiste Albouy, Marc Colombel, Amnon Zisman, Arie S. Belldegrun, and Allan J. Pantuck Tobias KlatteTobias Klatte Department of Urology, University of California-Los Angeles, Los Angeles, California , Jean-Jacques PatardJean-Jacques Patard Departments of Urology, University of Rennes, Rennes, France , Heiko WunderlichHeiko Wunderlich University of Jena, Jena, Germany , Rakhee H. GoelRakhee H. Goel Department of Urology, University of California-Los Angeles, Los Angeles, California , John S. LamJohn S. Lam Department of Urology, University of California-Los Angeles, Los Angeles, California , Kerstin JunkerKerstin Junker University of Jena, Jena, Germany , Jörg SchubertJörg Schubert University of Jena, Jena, Germany , Malte BöhmMalte Böhm University of Magdeburg, Magdeburg, Germany , Ernst P. AllhoffErnst P. Allhoff University of Magdeburg, Magdeburg, Germany , Fairooz F. KabbinavarFairooz F. Kabbinavar Department of Medicine, University of California-Los Angeles, Los Angeles, California , Maxime CrepelMaxime Crepel Departments of Urology, University of Rennes, Rennes, France , Luca CindoloLuca Cindolo Università del Sannio, Benevento, Italy , Alexandre De La TailleAlexandre De La Taille Centre Hospitalier Universitaire Henri Mondor, Creteil, France , Jacques TostainJacques Tostain University of Saint-Etienne, Saint-Etienne, France , Arnaud MejeanArnaud Mejean Necker Hospital, Paris, France , Michel SoulieMichel Soulie University of Toulouse, Toulouse, France , Laurent BellecLaurent Bellec University of Toulouse, Toulouse, France , Jean Christophe BernhardJean Christophe Bernhard University of Bordeaux, Bordeaux, France , Jean-Marie FerriereJean-Marie Ferriere University of Bordeaux, Bordeaux, France , Christian PfisterChristian Pfister University of Rouen, Rouen, France , Baptiste AlbouyBaptiste Albouy University of Rouen, Rouen, France , Marc ColombelMarc Colombel University of Lyon, Lyon, France , Amnon ZismanAmnon Zisman Tel-Aviv University, Tel-Aviv, Israel , Arie S. BelldegrunArie S. Belldegrun Department of Urology, University of California-Los Angeles, Los Angeles, California , and Allan J. PantuckAllan J. Pantuck Department of Urology, University of California-Los Angeles, Los Angeles, California View All Author Informationhttps://doi.org/10.1016/j.juro.2007.01.122AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the prognosis, risk factors and relevance of the primary-free interval in a large cohort with metachronous bilateral renal cell carcinoma. Materials and Methods: We studied 120 patients with metachronous, bilateral renal cell carcinoma who were treated at 12 international academic centers. Logistic regression was performed to evaluate risk factors for contralateral metachronous renal cell carcinoma during followup. Disease specific survival was evaluated with univariate and multivariate analysis. Results: Median age at diagnosis of the first and second renal cell carcinomas was 54 and 62 years, respectively. The most common histological subtype was bilateral clear cell renal cell carcinoma (89% of cases). Familial renal cell carcinoma was found in 14% of patients, von Hippel-Lindau disease was found in 4% and nonfamilial renal cell carcinoma was found in 81%. The 15-year disease specific survival rates for the first and second renal cell carcinomas were 66% and 44%, respectively. Logistic regression revealed von Hippel-Lindau disease, a family history of renal cell carcinoma, multifocal first renal cell carcinoma and young patient age as independent risk factors for contralateral renal cell carcinoma after surgery for unilateral renal cell carcinoma. A longer primary-free interval was associated with a better prognosis. When calculating disease specific survival from the diagnosis of the first renal cell carcinoma, the primary-free interval was an independent prognostic factor. Conclusions: Long-term survival rates of metachronous, bilateral renal cell carcinoma are moderate. von Hippel-Lindau disease, a family history of renal cell carcinoma, multifocal first renal cell carcinoma and young patient age are independent risk factors for contralateral renal cell carcinoma. These risk factors support close and extended abdominal surveillance following nephrectomy for unilateral renal cell carcinoma. Patients with a longer primary-free interval have a more favorable prognosis. References 1 : Bilateral non-familial renal cell carcinoma. Ann Surg Oncol1998; 5: 548. Crossref, Medline, Google Scholar 2 : Bilateral kidney tumor: Therapy management and histopathological results with long-term follow-up of 66 patients. Urologe A2001; 40: 114. Google Scholar 3 : Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach. J Urol2003; 169: 895. Link, Google Scholar 4 : Diseases of the kidney. In: Urological Pathology. Edited by . Philadelphia: WB Saunders Co1997: 464. Google Scholar 5 : Bilateral renal cell carcinoma: influence of synchronous and asynchronous occurrence on patient survival. J Urol1982; 128: 913. Link, Google Scholar 6 : Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am2003; 30: 843. Google Scholar 7 : Bilateral renal cell carcinoma and renal cell carcinoma in the solitary kidney. J Urol1984; 132: 450. Link, Google Scholar 8 : Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer2000; 88: 2739. Google Scholar 9 : Metachronous bilateral Wilms' tumor: the importance of time interval to the development of a second tumor. Cancer1998; 82: 415. Google Scholar 10 National Cancer Institute: Surveillance, Epidemiology and End Results (SEER). Available at http://seer.cancer.gov. Accessed December 9, 2006. Google Scholar 11 : Multifocality in renal cell carcinoma: a bilateral event?. Urol Int1999; 63: 160. Google Scholar 12 : The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol2003; 169: 1276. Link, Google Scholar 13 : High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis. BJU Int2006; 97: 279. Google Scholar 14 : Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res1988; 48: 7310. Medline, Google Scholar 15 : Bilateral hypernephroma. Am J Roentgenol Radium Ther Nucl Med1973; 117: 104. Google Scholar 16 : Genetic identification of bilateral primary or metastatic nonpapillary renal cell carcinoma. BJU Int2000; 86: 208. Crossref, Medline, Google Scholar 17 : Distinct patterns of chromosomal losses in clinically synchronous and asynchronous bilateral renal cell carcinoma. J Urol2002; 168: 2637. Link, Google Scholar 18 : Cytogenetics of bilateral renal cell carcinoma. J Urol1989; 142: 697. Link, Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetailsCited byBabaian K, Merrill M, Matin S, Tamboli P, Tannir N, Jonasch E, Wood C and Karam J (2014) Partial Nephrectomy in the Setting of Metastatic Renal Cell CarcinomaJournal of Urology, VOL. 192, NO. 1, (36-42), Online publication date: 1-Jul-2014.Abreu A, Berger A, Aron M, Ukimura O, Stein R, Gill I and Desai M (2012) Minimally Invasive Partial Nephrectomy for Single Versus Multiple Renal TumorsJournal of Urology, VOL. 189, NO. 2, (462-467), Online publication date: 1-Feb-2013.Crispen P, Soljic A, Stewart G, Kutikov A, Davenport D and Uzzo R (2012) Enhancing Renal Tumors in Patients with Prior Normal Abdominal Imaging: Further Insight into the Natural History of Renal Cell CarcinomaJournal of Urology, VOL. 188, NO. 4, (1089-1094), Online publication date: 1-Oct-2012. Volume 177Issue 6June 2007Page: 2081-2087 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordskidneycarcinomasecond primaryprognosisneoplasmsrenal cellriskMetricsAuthor Information Tobias Klatte Department of Urology, University of California-Los Angeles, Los Angeles, California More articles by this author Jean-Jacques Patard Departments of Urology, University of Rennes, Rennes, France Financial interest and/or other relationship with Bayer, Pfizer and Wilex. More articles by this author Heiko Wunderlich University of Jena, Jena, Germany More articles by this author Rakhee H. Goel Department of Urology, University of California-Los Angeles, Los Angeles, California More articles by this author John S. Lam Department of Urology, University of California-Los Angeles, Los Angeles, California More articles by this author Kerstin Junker University of Jena, Jena, Germany More articles by this author Jörg Schubert University of Jena, Jena, Germany More articles by this author Malte Böhm University of Magdeburg, Magdeburg, Germany More articles by this author Ernst P. Allhoff University of Magdeburg, Magdeburg, Germany More articles by this author Fairooz F. Kabbinavar Department of Medicine, University of California-Los Angeles, Los Angeles, California More articles by this author Maxime Crepel Departments of Urology, University of Rennes, Rennes, France More articles by this author Luca Cindolo Università del Sannio, Benevento, Italy More articles by this author Alexandre De La Taille Centre Hospitalier Universitaire Henri Mondor, Creteil, France More articles by this author Jacques Tostain University of Saint-Etienne, Saint-Etienne, France Financial interest and/or other relationship with Pierre Fabre. More articles by this author Arnaud Mejean Necker Hospital, Paris, France Financial interest and/or other relationship with Bayer and Pfizer. More articles by this author Michel Soulie University of Toulouse, Toulouse, France More articles by this author Laurent Bellec University of Toulouse, Toulouse, France More articles by this author Jean Christophe Bernhard University of Bordeaux, Bordeaux, France More articles by this author Jean-Marie Ferriere University of Bordeaux, Bordeaux, France More articles by this author Christian Pfister University of Rouen, Rouen, France More articles by this author Baptiste Albouy University of Rouen, Rouen, France More articles by this author Marc Colombel University of Lyon, Lyon, France More articles by this author Amnon Zisman Tel-Aviv University, Tel-Aviv, Israel More articles by this author Arie S. Belldegrun Department of Urology, University of California-Los Angeles, Los Angeles, California More articles by this author Allan J. Pantuck Department of Urology, University of California-Los Angeles, Los Angeles, California More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)